Cardiovascular risk reduction with once-weekly semaglutide in subjects with type 2 diabetes: a post hoc analysis of gender, age, and baseline CV risk profile in the SUSTAIN 6 trial

Date first appeared online	06/06/2019
DOI	10.1186/s12933-019-0871-8
Authors	Bain S.
Journal Name	Cardiovascular Diabetology
Volume	18

Documents

• 50453.pdf , Book, Released under the terms of a Creative Commons Attribution 4.0 International License (CC-BY).